Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00843791 · ClinicalTrials.gov registry record · NA
Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin
A NA study, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT00843791: Clinical Trial NA study, sponsored by Oregon Health and Science University.
NCT00843791 is a NA study that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00843791, a NA study, was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about how insulin resistance (inability to process glucose correctly resulting in mildly elevated glucose levels) affects the hormone ghrelin.
Primary Outcome
The primary outcome of this study will be the comparison of ghrelin suppressibility (total and acylated) in response to meals obese subjects before and after 3-months therapy with a thiazolidinedione.
Interventions
- DRUG placebo
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-05 |
| Phase | NA |
Why NCT00843791 stopped before completion
NCT00843791 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00843791 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00843791 about?
NCT00843791 is a clinical study titled "Ghrelin Regulation and Structure: Effect of Thiazolidinedione Therapy on Ghrelin". The purpose of this study is to learn more about how insulin resistance (inability to process glucose correctly resulting in mildly elevated glucose levels) affects the hormone ghrelin.
What is the current status of trial NCT00843791?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2009-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00843791?
The interventions under investigation include: placebo (DRUG), pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00843791?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00843791's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia